In a child with Kawasaki disease whose fever has persisted for more than 10 days, should intravenous immunoglobulin (IVIG) still be administered?

IVIG Should Still Be Administered Beyond 10 Days in Kawasaki Disease if Active Inflammation Persists

Yes, IVIG should be given to children with Kawasaki disease presenting after day 10 of fever if they have ongoing systemic inflammation (elevated ESR or CRP >3.0 mg/dL) or coronary artery aneurysms, but it should NOT be given if fever has resolved and laboratory values have normalized with a normal echocardiogram 1.

Clinical Decision Algorithm

When to Treat After Day 10:

Administer IVIG (2 g/kg single dose) if ANY of the following are present:

• Persistent fever without other explanation
• Elevated inflammatory markers (CRP >3.0 mg/dL or elevated ESR)
• Coronary artery aneurysms detected on echocardiogram (Z-score >2.5)

Do NOT administer IVIG if ALL of the following are true:

• Fever has completely resolved
• Laboratory values have normalized
• Echocardiogram shows no coronary abnormalities

Evidence and Rationale

The 2017 American Heart Association guidelines explicitly address this scenario 1. The key principle is that active inflammation, not just the calendar day of illness, determines treatment need. While IVIG is optimally given within the first 10 days to prevent coronary complications, delayed diagnosis is common and late treatment remains beneficial for controlling ongoing inflammation.

Effectiveness of Late IVIG Treatment

Research evidence shows that IVIG given after day 10 effectively resolves inflammation but is less effective at preventing coronary artery abnormalities 2. A Japanese study comparing patients treated on days 11-20 versus days 4-8 found:

• Similar inflammatory response (comparable reductions in WBC, neutrophils, and CRP)
• Slightly lower need for additional treatments in the late group (12% vs 16%)
• Significantly higher incidence of coronary artery lesions in the late group (27% vs 1%) during convalescence

However, among patients who had not yet developed coronary abnormalities before initial treatment, the proportions developing new lesions during the acute phase were similar (8% vs 8%) 2.

Critical Caveats

The Window of Opportunity

The primary goal of IVIG is preventing coronary artery damage, not just treating fever. The longer the delay in treatment, the higher the risk of irreversible coronary damage 1, 2. This is why:

1. Early diagnosis remains paramount - every effort should be made to diagnose and treat within the first 10 days
2. Late treatment is still worthwhile - it controls inflammation and may prevent progression of existing coronary changes
3. Patients with established aneurysms still benefit - IVIG helps control ongoing vasculitis

Assessment Before Late Treatment

Before administering IVIG after day 10, obtain:

• Inflammatory markers: ESR and CRP to document active inflammation
• Echocardiogram: Assess for coronary artery involvement (measure Z-scores of coronary arteries)
• Complete blood count: Baseline values before treatment

Standard Dosing Applies

Use the same evidence-based regimen regardless of timing:

• IVIG 2 g/kg as a single infusion over 10-12 hours 1
• Aspirin: 80-100 mg/kg/day (divided every 6 hours) in the US, or 30-50 mg/kg/day in other regions 1

Management of IVIG Resistance in Late Presenters

Approximately 15-20% of patients fail to respond to initial IVIG 1, 3. For late presenters who remain febrile 36-48 hours after IVIG completion, consider:

Second-line options:

• Repeat IVIG (2 g/kg) - traditional approach
• Infliximab (5 mg/kg over 2 hours) - shown to reduce fever duration and hospitalization with similar coronary outcomes 1
• Corticosteroids - methylprednisolone pulse therapy (30 mg/kg/day for 3 days) or longer courses with oral taper 1

Common Pitfalls to Avoid

1. Don't withhold treatment solely based on day of illness - active inflammation is the key determinant
2. Don't assume it's "too late" - even patients presenting at 2-3 weeks with ongoing inflammation may benefit
3. Don't forget recurrent KD - patients with a repeat episode after complete resolution should receive standard therapy regardless of timing 1
4. Don't delay live vaccines inappropriately - measles, mumps, and varicella vaccines should be deferred for 11 months after high-dose IVIG 1

The evidence strongly supports treating late presenters with active inflammation, as the benefits of controlling vasculitis outweigh the reduced efficacy in preventing coronary complications compared to early treatment.